Sendai virus-based RSV vaccine protects African green monkeys from RSV infection

Highlights ► SeVRSV, a recombinant Sendai virus expressing RSV F, was tested in AGM. ► SeVRSV elicited antibody responses against SeV and RSV. ► SeVRSV fully protected AGM from lower respiratory tract RSV infection. ► SeVRSV caused no clinically relevant adverse events. ► SeVRSV is an attractive RSV...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2012-01, Vol.30 (5), p.959-968
Main Authors: Jones, Bart G, Sealy, Robert E, Rudraraju, Rajeev, Traina-Dorge, Vicki L, Finneyfrock, Brad, Cook, Anthony, Takimoto, Toru, Portner, Allen, Hurwitz, Julia L
Format: Article
Language:English
Subjects:
Administration, Inhalation
Administration, Intranasal
Allergy and Immunology
Animals
antibodies
Antibodies, Viral - blood
Cercopithecus aethiops
children
Chlorocebus aethiops
clinical trials
Disease Models, Animal
Drug Carriers
genes
Genetic Vectors
Genomes
humans
immune response
Jennerian vaccine
Laboratory animals
mice
nose
Parainfluenza virus
Protective immunity
Respiratory syncytial virus
Respiratory Syncytial Virus Infections - prevention & control
Respiratory Syncytial Virus Vaccines - administration & dosage
Respiratory Syncytial Virus Vaccines - adverse effects
Respiratory Syncytial Virus Vaccines - genetics
Respiratory Syncytial Virus Vaccines - immunology
Respiratory tract
RNA polymerase
secondary immunization
Sendai virus
Sendai virus - genetics
vaccination
Vaccines
Vaccines, Synthetic - administration & dosage
Vaccines, Synthetic - adverse effects
Vaccines, Synthetic - genetics
Vaccines, Synthetic - immunology
Viral Fusion Proteins - genetics
Viral Fusion Proteins - immunology
viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights ► SeVRSV, a recombinant Sendai virus expressing RSV F, was tested in AGM. ► SeVRSV elicited antibody responses against SeV and RSV. ► SeVRSV fully protected AGM from lower respiratory tract RSV infection. ► SeVRSV caused no clinically relevant adverse events. ► SeVRSV is an attractive RSV vaccine candidate.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2011.11.046